BeOne Medicines: Q2 2026 revenue up 30% to $1.7B, net income up 151%, driven by strong product sales and margin gains

BeOne Medicines reported Q2 2026 revenue of $1.7B, a 30% year-over-year increase, with net income surging 151% to $237M. Growth was driven by strong sales of BRUKINSA® and TEVIMBRA®, alongside improved margins. The company also expanded its New Jersey facility, achieved positive Phase 3 results, and maintains robust liquidity to support growth and debt obligations.

Q2 2026 revenues rose 30% year-over-year to $1.7B, with net income up 151% to $237M, driven by strong BRUKINSA® and TEVIMBRA® sales and improved margins. The company expanded its NJ facility, reported positive Phase 3 results, and maintains strong liquidity to fund growth and meet debt obligations.

Original document: BeOne Medicines Ltd. Class A [688235] SEC 10-Q Quarterly Report — Aug. 5 2026

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.